Alnylam Pharmaceuticals
ALNY
#1123
Rank
NZ$37.72 B
Marketcap
NZ$281.63
Share price
3.42%
Change (1 day)
-64.01%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$35.04

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$35.58. In 2025 the company made an earnings per share (EPS) of NZ$3.16.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$35.041008.67%
2025NZ$3.16
2023NZ-$6.34-62%
2022NZ-$16.6829.03%
2021NZ-$12.93-3.36%
2020NZ-$13.38-8.48%
2019NZ-$14.627.67%
2018NZ-$13.5839.74%
2017NZ-$9.7212.94%
2016NZ-$8.6038.84%
2015NZ-$6.20-32.88%
2014NZ-$9.23259.44%
2013NZ-$2.57-31.25%
2012NZ-$3.74

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$9.43-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$3.56-90.00%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$84.37 137.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.72-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.31-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.34-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$0.81-97.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ-$5.98-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA